Comparison of oral thiazides vs intravenous thiazides vs tolvaptan in combination with loop 
diuretics for diuretic resistant decompensated heart failure  
 
 
NCT 02606253  
Document Date 8/31/2019  
 
 
Protocol Version  #: 6  1 
Protocol Date: 10/27/2017  
 
 
 
 
 
 
 
Comparison of oral thiazides vs intravenous thiazides vs tolvaptan in combination with loop 
diuretics for diuretic resistant decompensated heart failure  
 
Princip al Investigator:  
Zachary L. Cox, PharmD  
 
 
 
 
Co-Investigators:  
Rebecca Hung , M.D., Associate [CONTACT_3348] of Cardiovascular Medicine  
Vanderbilt University  
 
Daniel J Lenihan, M.D., [CONTACT_3348] of Cardiovascular Medicine  
Vanderbilt University  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Version  #: 6  2 
Protocol Date: 10/27/2017 Table of Contents:  
 
Study Schema  
1.0 Background  
2.0 Rationale and Specific Aims  
3.0 Inclusion/Exclusion Criteria  
4.0 Enrollment/Randomization  
5.0 Study Procedures  
6.0 Risks of Investigational Agents/Devices (side effects)  
7.0 Reporting of Adverse Events or Unanticipated Problems involving Risk to 
Participants or Others  
8.0 Study Withdrawal/Discontinuation  
9.0 Statistical Considerations  
10.0 Privacy/Confidentiality Issues  
11.[ADDRESS_220499] Retention  
 
Appendices  
Appendix A: Schedule of Study Assessments  
Appendix B: Patient -Reported Congestion Score  
 
 
Protocol Version  #: 6  3 
Protocol Date: 10/27/2017 1.0 Backgroun d 
 
Loop diuretic therapy is the cornerstone of heart failure (HF) symptom management.  Symptoms 
of fluid retention and congestion are responsible for 90% of HF hospi[INVESTIGATOR_602], and almost all 
(86% - 97%) patients hospi[INVESTIGATOR_186585] (IV ) loop diuretics.1,2-4  The 
incidence of diuretic resistance is unknown, given the lack of a consensus definition, but 
resistance is reported to occur in 25 -35% of heart failure patients. 5-7 Despi[INVESTIGATOR_186586], guidelines by [CONTACT_186608] (HFSA) and the American College  of Cardiology Foundation/American 
Heart Association  (ACCF/AHA) provide nonspecific guidance on diuretic  regimen design in 
response to diuretic resist ance. Both guidelines recommend (LOE IIA, Class B) the addition of a 
second type of diuretic (options listed include oral metolazone and intravenous chlorothiazide). 8,9 
As expected, 57% of physician questions about advanced HF management in a recent surve y 
concerned diuretic titration.10 
 
Addition of a second diuretic is a common practice to overcome diuretic resistance, despi[INVESTIGATOR_186587]. A 2010 literature review of combining thiazide and 
loop diuretics found, â€œ The aggregate body of literature is limited by [CONTACT_186609], 
study design with lack of control groups, heterogeneous patient populations, wide variation in 
diuretic regimens, and focus on physiologic rather than clinical outcomes.â€[ADDRESS_220500] of 
combination diuretic regimens, predisposing patie nts to cardiac arrhythmias. 11 Furthermore, each 
agent has it limitations: metolazone is subjected to erratic absorption due to its oral dosage form; 
whereas, intravenous chlorothiazide over comes the absorption issue but is more costly.12-[ADDRESS_220501] (Efficacy of 
Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan) trials the addition of 
30 mg tolvaptan daily was evaluated compared to IV lo op diuretics in > 4,[ADDRESS_220502] day, and weights at 
discharge or day 7 were 0.6 kg lower in trial A and 0.9 kg lower in trial B (p <  .001). Most 
notably, no study reported hypok alemia with the combination of loop diuretics and tolvaptan.15-17 
Another study demonstrated that 80mg furosemide plus 30mg of tolvaptan provided a reducing of 
1.48kg (Â± 1.14kg) at [ADDRESS_220503] pros pective trials comparing three 
different medications in addition to loop diuretics. By [CONTACT_14662] a prescriptive algorithm for loop 
diuretic dosing and other medical therapi[INVESTIGATOR_186588], the study will address 
many of the limitations of p revious studies such as the lack of a control group, retrospective 
design, and wide variations of both loop and thiazide diuretic regimens.13, 14 Metolazone will be 
 
Protocol Version  #: 6  4 
Protocol Date: 10/27/[ADDRESS_220504] -of-care thiazide to mirror current clinical perceptions and to rep licate a 
recent landmark diuretic studyâ€™s thiazide use.11, [ADDRESS_220505] intravenous chlorothiazide will require equivalent cumulative potassium repletion at 48 
hours compared to oral metolazone. Hypokalemia as not been reported with the combination of 
tolvaptan a nd loop diuretics, likely due to tolvaptanâ€™s distinctive mechanism of action. We expect 
tolvaptan will require less cumulative potassium repletion at [ADDRESS_220506] -of-care oral metolazone when combined with standardized loop diuretic 
dosing for diuretic resistance in acute heart failure  
The average wholesale price for one dose of each agent according to Redbook online is $1.50, 
$357, and $[ADDRESS_220507] difference of tolvaptan tablets compared to 
metolazone tablets.  
 
 
 
 
Protocol Version  #: 6  5 
Protocol Date: 10/27/2017 3.0 Inclusion/Exclusion Criteria  
 
Inclusion C riteria  
Criteria for inclusion will be:  
â€¢ Age of 18 years or older  
â€¢ Hospi[INVESTIGATOR_186589].  
o Hypervolemia will be diagnosed by [CONTACT_186610] (i) 
pulmonary art ery catheterization with a pulmonary capi[INVESTIGATOR_186590] 19mmHg plus a systemic physical exam finding of hypervolemia 
(peripheral edema, ascites, or pulmonary edema on auscultation) or (ii) in the 
absence of pulmonary artery catheterizati on data 2 of the following signs or 
symptoms: peripheral edema ascites, jugular venous pressure > 10mmHg, or 
pulmonary edema on chest x -ray.  
o Loop diuretic resistance is defined as a provider decision to pursue combination 
diuretic therapy because of failu re to reach provider defined adequate diuresis 
(can not exceed urine output of [ADDRESS_220508] 12 hours) despi[INVESTIGATOR_186591] a furosemide equivalent of at least 240mg/day 
over at least the past 12 hours (40mg furosemide = 20 mg torsemide = 1mg 
bumetanide).  
â€¢ Standard -of-care monitoring, including [ADDRESS_220509] and a basic metabolic panel laboratory assessment twice daily during the study 
period.  
 
Exclusion Criteria  
Candidates will be excluded if they meet any of the following crite ria at the time of enrollment:  
â€¢ Decision to pursue hemodialysis by a nephrologist  
â€¢ estimated glomerular filtration rate by [CONTACT_175560] < 15ml/min/m2 
â€¢ systolic blood pressure < 85mmHg  
â€¢ pregnancy * or breastfeeding  
â€¢ serum potassium < 3.0mEq/L  
â€¢ serum s odium > 145mEq/L or < 1 30mEq/L  
â€¢ severe malnutrition  
â€¢ advanced liver disease  
â€¢ inabili ty to perform standing weights  
â€¢ inability to collect and measure urine with either a foley catheter or urine collection 
containers  
â€¢ concomitant therapy with strong CYP3A4 inhibitors/inducers (systemic ketoconazole, 
clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir, nefozodone, 
rifampin, rifabutin, rifapentin, phenytoin, phenobarbital, carbamazepi[INVESTIGATOR_050], St. Johnâ€™s 
Wort), p -glycoprotein inhibitors (cyclosporine, erythromycin, tacrolimus, dronedarone, 
quinidine, or verapamil)  
â€¢ non-study diuretics (spi[INVESTIGATOR_186592] >75mg/day, eplerenone > 75mg/day, non -study 
thiazides or loop diuretics, or systemic acetaz olamide, triamterene, or amiloride therapy)  
â€¢ Thiazide mediation administered in the previous 24 hours prior to randomization  
 
*Pregnancy: In women of childbearing age who are not in menopause per patient report during 
screening, a serum pregnancy test will be ordered and negative prior to enrollment.  
 
 
 
Protocol Version  #: 6  6 
Protocol Date: 10/27/2017 4.0 Enrollment/Randomization  
 
We will conduct a single  center, randomized, double -blind, double -dummy, parallel design trial 
comparing oral metolazone, intravenous chlorothiazide, and oral tolvaptan in combination with 
loop diuretics in patients hospi[INVESTIGATOR_186593]. The duration o f the 
study will be [ADDRESS_220510] dose of the study thiazide or tolvaptan medication. 
Vanderbilt University Medical center will be the study  site. IRB approval will be obtained from 
the Vanderbilt Univeristy Medical Center IRB .  
 
All patients wil l provide informed consent prior to enrollment. After enrollment, a ll patients will 
be randomized in a 1:1:[ADDRESS_220511] of Care Therapi[INVESTIGATOR_186594] a 2L/day fluid restriction and a 2g/day sodium restriction. 
Decisions regarding the initiation, titration, or discontinuation of standard heart failure 
medications (ACEI, ARB, Aldosterone Antagonists, Beta Blockers, digoxin,  hydralazine, 
nitrates) are left to the discretion of the treating physicians.  All electrolyte repletion, loop diuretic 
dose titration, and concomitant therapi[INVESTIGATOR_186595]â€™s discretion.  
To prevent conf ounding heterogeneity in the diuretic treatment approach, a stepped care 
algorithm similar to the CARRESS -HF19 trial will be utilized for loop diuretics, both initial doses 
and subsequent dose changes, and for concomitant inotropes and vasodilators. The st epped care 
algorithm and the initial diuretic treatment regimen are delineated in Study Flow Diagram below. 
A minimum furosemide equivalent dose of 580mg/24hrs (100mg IV bolus + 20mg/hr infusion 
rate) must be ordered at enrollment.  
 
5.2 Randomization  
All patients will be randomized in a 1:1:1 fashion at VUMC using an electronic randomization 
tool embedded in REDCAP.  Patients will be randomized to either : 
1) intravenous chlorothiazide 500mg IV Q12H +  an oral placebo capsule Q12H  
2) intravenous  placebo infusion Q12H + a capsule containing oral metolazone 5mg PO 
Q12H  
3) intravenous placebo infusion Q12H + a capsule containing oral tolvaptan 30mg once 
daily and placebo capsule in the evening dose.  
 
(Relative potency21, 22: Metolazone 100 fold more potent than chlorothiazide)  
 
 
 
 
 
 
 
 
 
 
ÂÂ‹Â–Â‹ÂƒÂÂ‘Â‘Â’Â‹Â—Â”Â‡Â–Â‹Â…Â‡Â‰Â‹ÂÂ‡Â
 Í´Í¶ÂŠÂ‘Â—Â”Â‡Â‹Â‰ÂŠÂ–ÂŠÂƒÂÂ‰Â‡Â•Â•Â‡Â•Â•ÂÂ‡ÂÂ–

 ÂÂ–Â”Â›Â‘Â‘Â’
Â‹Â—Â”Â‡Â–Â‹Â…Â‘Â•Â‡
È‹ÂˆÂ—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡
Â‡Â“Â—Â‹Â˜ÂƒÂÂ‡ÂÂ–
ÂÂ‰È€Â†ÂƒÂ›ÈŒÂÂ‹Â–Â‹ÂƒÂÂ”Â‹ÂƒÂÂ‘Â‘Â’
Â‹Â—Â”Â‡Â–Â‹Â…Â‘Â•Â‡
Â‡Â‰Â‹ÂÂ‡Â Í´Í¶Í²Ç¦Í¶ÍºÍ²ÂÂ‰ 	Â—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡
È‹Â‘Â”Â‡Â“Â—Â‹Â˜ÂƒÂÂ‡ÂÂ–ÈŒ
Í³Í²Í²ÂÂ‰Â‘ÂÂ—Â•Îª
Í´Í²ÂÂ‰È€ÂŠÂ”
Â‡Â‰Â‹ÂÂ‡Â ÎµÍ¶ÍºÍ²ÂÂ‰ 	Â—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡
È‹Â‘Â”Â‡Â“Â—Â‹Â˜ÂƒÂÂ‡ÂÂ–ÈŒ
Í³Í²Í²ÂÂ‰Â‘ÂÂ—Â•Îª
ÍµÍ²ÂÂ‰È€ÂŠÂ”
 Â—Â‰Â‰Â‡Â•Â–Â‡Â†Â‘Â‘Â’Â‹Â—Â”Â‡Â–Â‹Â…Â‘Â•Â‡
Â‡Â‰Â‹ÂÂ‡Â 	Â—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡È‹Â‘Â”Â‡Â“Â—Â‹Â˜ÂƒÂÂ‡ÂÂ–ÈŒ
Í³Í²Í²ÂÂ‰Â‘ÂÂ—Â•ÎªÍ´Í²ÂÂ‰È€ÂŠÂ”
Â‡Â‰Â‹ÂÂ‡Â 	Â—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡È‹Â‘Â”Â‡Â“Â—Â‹Â˜ÂƒÂÂ‡ÂÂ–ÈŒ
Í³Í²Í²ÂÂ‰Â‘ÂÂ—Â•ÎªÍµÍ²ÂÂ‰È€ÂŠÂ”
Â‡Â‰Â‹ÂÂ‡Â 	Â—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡È‹Â‘Â”Â‡Â“Â—Â‹Â˜ÂƒÂÂ‡ÂÂ–ÈŒ
ÍºÍ²ÂÂ‰Â‘ÂÂ—Â•ÎªÍºÍ²ÂÂ‰È€ÂŠÂ” Â›Â’Â‡Â”Â˜Â‘ÂÂ‡ÂÂ‹Â…	
Â™Â‹Â–ÂŠÎ´Í´Â‹Â
Â’ÂƒÂ•Â–Í³Í´ÂŠÂ‘Â—Â”Â•Â‘Â
Îµ	Â—Â”Â‘Â•Â‡ÂÂ‹Â†Â‡
Í´Í¶Í²ÂÂ‰È€Â†ÂƒÂ› Â‡Â–Â‘ÂÂƒÂœÂ‘ÂÂ‡Â‘Â”ÂƒÂ
ÂŠÂÂ‘Â”Â‘Â–ÂŠÂ‹ÂƒÂœÂ‹Â†Â‡ 

Â‘ÂÂ˜ÂƒÂ’Â–ÂƒÂÂ‘Â”ÂƒÂ 

Â‡Â–Â‘ÂÂƒÂœÂ‘ÂÂ‡Â‘Â”ÂƒÂ
ÂŠÂÂ‘Â”Â‘Â–ÂŠÂ‹ÂƒÂœÂ‹Â†Â‡

Â‘ÂÂ˜ÂƒÂ’Â–Âƒ
ÂÂ‘Â”ÂƒÂ

Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â 
Â–Í³Í´
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â 
Â–Í³Í´
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â 
Â–Í³Í´
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â 
Â–Í³Í´
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â 
Â–Í³Í´Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â 
Â–Í³Í´

Â‘ÂƒÂÇ£ÍµÇ¦Í·È€Í´Í¶ÂŠÂ”Â•
ÂˆÎ´ÍµÈ€Í´Í¶ÂŠÂ”Â•Ç£ÂÂ‘Â˜Â‡Â—Â’Â†Â‹Â—Â”Â‡Â–Â‹Â…Â‰Â”Â‹Â†
ÂˆÂƒÂ–Â‰Â‘ÂƒÂÇ£Â…Â‘ÂÂ–Â‹ÂÂ—Â‡Â…Â—Â”Â”Â‡ÂÂ– Â”Â‡Â‰Â‹ÂÂ‡Â
ÂˆÎµÍ·È€Í´Í¶ÂŠÂ”Â•Ç£Â…Â‘ÂÂ–Â‹ÂÂ—Â‡Â…Â—Â”Â”Â‡ÂÂ–Â”Â‡Â‰Â‹ÂÂ‡ÂÂ‘Â”
ÂÂ‘Â˜Â‡Â†Â‘Â™ÂÂ†Â‹Â—Â”Â‡Â–Â‹Â…Â‰Â”Â‹Â†
ÂÂ‘Â–Â”Â‘Â’Â‡Æ¬ÂƒÂ•Â‘Â†Â‹ÂÂƒÂ–Â‘Â”ÂÂ‰Â‘Â”Â‹Â–ÂŠÂ
ÂˆÍ´Í¶ÂŠÂ”Â‹Â•Â„Â‡ÂÂ‘Â™Â‰Â‘ÂƒÂÎ´Í³Í²Í²ÂÂÂ‰	Î´Í¶Í²Î¨Â‘Â”Â•Â›Â•Â–Â‘ÂÂ‹Â…Â†Â›Â•ÂˆÂ—ÂÂ…Â–Â‹Â‘ÂÇ£
Â‘ÂÂ•Â‹Â†Â‡Â”ÂƒÂ†Â†Â‹Â–Â‹Â‘ÂÂ‘ÂˆÂ†Â‘Â’ÂƒÂÂ‹ÂÂ‡Í´ÂÂ…Â‰È€ÂÂ‰È€ÂÂ‹ÂÂ‹Â
ÂƒÂ†Â†Â‹Â–Â‹Â‘ÂÂ–Â‘Â‹ÂÂ…Â”Â‡ÂƒÂ•Â‹ÂÂ‰Â†Â‹Â—Â”Â‡Â–Â‹Â…Â”Â‡Â‰Â‹ÂÂ‡Â

ÂˆÍ´Í¶ÂŠÂ”Â‹Â•Â„Â‡ÂÂ‘Â™Â‰Â‘ÂƒÂ	Î´Í¶Í²Î¨ÂƒÂ”Â†Â‹ÂƒÂ…ÂÂ†Â‡ÂšÂ‹Â•Â‡Â‹Â–ÂŠÂ‡Â”Â•Â—Â•Â’Â‡Â…Â–Â‡Â†Â‘Â”ÂÂ‡ÂƒÂ•Â—Â”Â‡Â†Â–Â‘Â„Â‡Â„Â‡ÂÂ‘Â™Í´Ç¤Í´ÂÂÈ€ÂÂ‹ÂÈ€Â
Í´Ç£Â‘ÂÂ•Â‹Â†Â‡Â”ÂƒÂ†Â†Â‹Â–Â‹Â‘ÂÂ‘Âˆ
Â†Â‘Â„Â—Â–ÂƒÂÂ‹ÂÂ‡Í´Ç¤Í·Ç¦Í·ÂÂ…Â‰È€ÂÂ‰È€ÂÂ‹ÂÂ‘Â”ÂÂ‹ÂÂ”Â‹ÂÂ‘ÂÂ‡
Í²Ç¤Í³Í´Í·È‚Í²Ç¤Í·ÂÂ…Â‰È€ÂÂ‰È€ÂÂ‹Â
ÂˆÍ´Í¶ÂŠÂ”Â‹Â•Â„Â‡ÂÂ‘Â™Â‰Â‘ÂƒÂÂ›Â•Â–Â‘ÂÂ‹Â…Îµ
Í³Í´Í²ÂÂÂ‰Â•Â‡Â˜Â‡Â”Â‡Â•Â›ÂÂ’Â–Â‘ÂÂ•Â‘ÂˆÂ†Â›Â•Â’ÂÂ‡ÂƒÇ£Â‘ÂÂ•Â‹Â†Â‡Â”ÂƒÂ†Â†Â‹Â–Â‹Â‘ÂÂ‘ÂˆÂ‹Â–Â”Â‘Â‰ÂÂ›Â…Â‡Â”Â‹Â

Â‡Â–Â‘ÂÂƒÂœÂ‘ÂÂ‡
Îª
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â
Ç¡Ç¡Â‘Â” Í³Í´
Â‘ÂÂ˜ÂƒÂ’Â–ÂƒÂ
Îª
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â
Ç¡Ç¡Â‘Â” Í³Í´ÂŠÂÂ‘Â”Â‘Â–ÂŠÂ‹ÂƒÂœÂ‹Â†Â‡
Îª
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â
Ç¡Ç¡Â‘Â” Í³Í´
Â‡Â–Â‘ÂÂƒÂœÂ‘ÂÂ‡
Îª
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â

Ç¡Ç¡Â‘Â”
Í³Í´
Â‘ÂÂ˜ÂƒÂ’Â–ÂƒÂ
Îª
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â

Ç¡Ç¡Â‘Â”
Í³Í´
ÂŠÂÂ‘Â”Â‘Â–ÂŠÂ‹ÂƒÂœÂ‹Â†Â‡
Îª
Â‘Â‘Â’
Â‡Â‰Â‹ÂÂ‡Â
Ç¡Ç¡Â‘Â”
Í³Í´
Í¶ÍºÂŠÂ‘Â—Â”Â‡Â‹Â‰ÂŠÂ–ÂŠÂƒÂÂ‰Â‡
Â•Â•Â‡Â•Â•ÂÂ‡ÂÂ–ÂƒÂÂ†
ÂÂ†Â‘ÂˆÂ–Â—Â†Â›

Protocol Version #: 6 
Protocol Date: 10/27/2017  8 5.3 Blinding  
This study will be double blinded. Blinding will be performed by [CONTACT_186611]â€™s 
investigational drug service pharmacy. A double -dummy strategy will prevent investigators from 
knowing the treatment arm during observation.  
 
5.4 Study Outcomes  
The prim ary outcome will be 48 -hour standing scale weight change (kg) from enrollment among 
the metolazone, intravenous chlorothiazide, and tolvaptan arms, using metolazone group as the 
comparator group for all other groups.  
Secondary outcomes, using metolazone a s the comparator group for each, will be:  
â€¢ 48 hour net urine output (mls)  
â€¢ mean change in serum creatinine,  blood urea nitrogen, and eGFR at 24 hours, 48hours, 
and at hospi[INVESTIGATOR_2345]  
â€¢ mean change in diuretic efficiency at 24 and 48 hours from baseline valu e at enrollment  
â€¢ mean change in serum potassium at 24 and 48 hours from baseline value at enrollment  
â€¢ mean change in serum sodium at 24 hours, 48hrs, and at discharge from baseline value at 
enrollment  
â€¢ cumulative dose of potassium (mEq) and magnesium (g) supp lementation administered at 
24 and 48 hours  
â€¢ incidence of severe hypokalemia  
â€¢ need for escalation in study -directed loop diuretic therapy at 24 and 48 hours  
â€¢ addition of vasoactive or inotropic medication at 24 and 48 hours  
â€¢ Treatment failure ( definition below ) 
â€¢ Patient -scored congestion visual analog scale score at baseline, 24 and 48 hours 
(Appendix B)  
â€¢ new cardiac arrhythmias (atrial and ventricular) during the study period  
â€¢ receipt of inotropic therapy, dopamine, or nitroglycerin; requirement of ultrafiltratio n or 
hemodialysis during index hospi[INVESTIGATOR_059]  
â€¢ in-hospi[INVESTIGATOR_34380]  
â€¢ pharmacoeconomic analysis of the direct costs in each arm including the cost of:  
o study medication  
o additional non -trial protocol laboratory analysis cost related to monitoring of 
electrol ytes 
o treatment of study medication related adverse effects (arrhythmias, hypotension, 
electrolyte repletion)  
o escalation of loop diuretic therapy doses  
o addition of additional therapi[INVESTIGATOR_186596] (inotropic therapy, 
vasodilators)  
o new initiation of renal replacement therapi[INVESTIGATOR_014] (hemodialysis or ultrafiltration)  
â€¢ Spot urinary electrolytes and diuretic urine concentration  
â€¢ Pharmacokinetics and pharmacodynamics of the diuretics in the urine and blood  
â€¢ Fractional excretion of sodium  
 
5.5 Study D efinitions  
â€¢ Urine output: Total urine volume (ml) from time of study enrollment to 48 hours  
â€¢ Hypokalemia: Serum potassium value < 3.5mEq/L  
â€¢ Severe Hypokalemia: Serum potassium value < 3.0mEq/L  
â€¢ Hyponatremia: Serum sodium value < 135mEq/L  
Protocol Version #: 6 
Protocol Date: 10/27/2017  9 â€¢ Severe Hyponatremia:  Serum sodium value < 130mEq/L and a decrease of 5mEq/L or 
more from enrollment serum sodium  
â€¢ Overcorrection of serum sodium: increase in serum sodium from baseline by >12mEq/L 
in 24 hours, increase in >8mEq/L in 12 hours, or receipt of intravenous fluids b ecause of 
symptoms of overcorrection of serum sodium regardless of the numerical rise  
â€¢ Hypomagnesiemia: Serum magnesium value < 2mEq/L  
â€¢ Diuretic efficiency = 24hr urine output/ 24hr Lasix equivalents in milligrams  
â€¢ Weight: Standing weight on the same scale a s used for baseline weight measurement  
â€¢ New Atrial Arrhythmia: A â€œnewâ€ diagnosis of atrial arrhythmia (includes atrial 
fibrillation, atrial flutter, ectopic atrial tachycardia) lasting > 30 seconds OR any atrial 
arrhythmia which causes hemodynamic instabili ty (MAP < 60 and requiring intervention)  
â€¢ New Ventricular Arrhythmia: Ventricular tachycardia lasting longer than 30 seconds, or 
frequent non -sustained VT causing hemodynamic instability with MAP < 60 mmHg 
requiring intervention or > 1 intra-cardiac defibrillation or external cardiac defibrillation 
shock or ventricular fibrillation requiring defibrillation  
â€¢ Hypotension: SBP < [ADDRESS_220512] 
30 minutes or symptomatic hypotension necessi tating clinical intervention (defined as 
vasopressor support, intravenous fluid boluses, or initiation of inotropes)  
â€¢ Treatment failure: Patients requiring additional non -study diuretic (spi[INVESTIGATOR_186592] 
>75mg/day, eplerenone > 75mg/day, non -study thiaz ides (at a dose of metolazone 2.5mg 
or greater equivalence)  or loop diuretics, or systemic acetazolamide  (for diuretic 
indication) , triamterene, or amiloride therapy) at any time during the 48 -hour 
randomization period. These patients will be considered tr eatment failures for the purpose 
of analysis of the primary endpoint and all secondary endpoints.  
â€¢ Patients whose cardiologist adds inotropic or vasodilator medications will not be 
considered treatment failures. Patients who require an increase in the loop  diuretic 
regimen will also not be considered treatment failures.  
â€¢ Medication costs will be defined as the Redbook average wholesale price at the time of 
the trial to reduce inter -institutional price differences and improve external validity of the 
analysi s. 
 
5.6 Study Outcome Timeline  
Day 1: Baseline standing weight, BMP every 12 hours, urine collection, 20ml blood collection  
dyspnea score.  
Day 2: 24 hour urine collection /quantification , BMP every 12 hours, 24 hour standing weight, 
20ml blood collection, 24 hour dyspnea score, receipt of non -study diuretics, need of new 
inotropes or vasodilators  
Day 3: 48 urine collection/ quantification, 48 hour standing weight, 20ml blood collection, 48 
hour dyspnea score, receipt of non -study diuretics, need of new inotropes or vasodilators.  
End of study.  
Day 30 (+/ - 2 days): Telephone contact [CONTACT_186612] 30 days:  
â€¢ ER visits and reason for visits  
â€¢ Hospi[INVESTIGATOR_186597]  
â€¢ Serious adverse events  
 
5.[ADDRESS_220513] 20 ml of blood (10ml of serum and 10ml of plasma) at baseline (after consent), at 
24 hours, and at 48 hours/study conclusion. We will serially collect urine produced during the 
study period for analysis. Analyses will include fractional exc retion of sodium, diuretic 
pharmacokinetics/dynamics, and measures of hemoconcentration.    
Protocol Version #: 6 
Protocol Date: 10/27/2017  10 6.0 Risks  
This study will evaluate the addition of an oral thiazide, intravenous thiazide, or tolvaptan to 
augment intravenous loop diuretic therapy in patients with  hypervolemic decompensated heart 
failure and diuretic resistance to adequately dosed loop diuretic monotherapy. Augmentation of 
loop diuretic therapy with a second diuretic (commonly a thiazide) is considered the standard -of-
care in diuretic resistance an d is endorsed by [CONTACT_34129]/ACCF and HFSA guidelines.8,[ADDRESS_220514] study evaluated 4,133 patients with decompensated heart failure randomized to 
placebo or tolvaptan for 60 days. The in -hospi[INVESTIGATOR_186598] (6.5%) and placebo (5.5%). The most common adverse effects of tolvaptan  in these 
trials have been thirst (16%), dry mouth (8.4%), and polyuria. Hypernatermia occurred in 1.7% of 
tolvaptan patients vs 0.5% of placebo patients. Acute kidney injury, hypotension, and potassium 
derangements are not associated with tolvaptan therap y. As our duration of study is only [ADDRESS_220515] diuresis augmentation with a thiazide.  
Hypernatremia/Over -correction of Serum Sodium  
While hyponatremia is not the target population of this study, patients with a serum sodium range 
of 130 -145mEq/L are eligible to participate. Relative to the thiazide arm, patients with 
hyponatremia randomized to tolvaptan are at the unique, albeit rare, risk of over -correctio n of 
serum sodium. Overcorrection of sodium is commonly defined as an increase in serum sodium by 
[CONTACT_726] 12mEq/L in [ADDRESS_220516] likely to occur when 
the serum sodium is < 125mEq/L at baseline, which is an exclusion c riterion of our study.  The 
SALT studies included patients with hyponatremia (serum sodium < 135mEq/L) from various 
disease states, including heart failure.  Only 5 patients (2.2%) of patients experienced a rise if 
serum sodium > 12mEq/L during any [ADDRESS_220517] developed 
osmotic demyelination syndrome (ODS). The FDA package insert for tolvaptan records that cases 
of ODS have occurr ed in post -marketing surveillance. In our study, we will only randomize 20 
patients to tolvaptan, calculating to 1 -2 patients with hyponatremia being randomized to 
tolvaptan. The low rate of overcorrection in literature, small sample size, exclusion criter ia 
(sodium < 130 mEq/L, advanced liver disease, severe malnutrition), short duration of therapy in 
our trial, and twice daily serum sodium monitoring makes the risk of a patient experiencing 
overcorrection of serum sodium low in our study. All patients will be hospi[INVESTIGATOR_186599].  
To minimize this risk, patients who are at highest risk of ODS at enrollment (serum sodium < 
130mEq/L) will receive a serum sodium assessment [ADDRESS_220518] udy diuretic. 
If the serum sodium increases > 8mEq/L from baseline at 12 hours, the will receive protocolized 
management to prevent ODS.  
1) Intravenous D5W at 3ml/kg/hr  
2) Repeat serum sodium every 2 hours  
3) Neurologic monitoring for symptoms such as speech dist urbances, altered mental status, 
and seizure activity  
4) D5W and every 2 hour serum sodium labs will be continued until the serum sodium is < 
8mEq/L above baseline sodium  
Patients will continue the loop diuretic therapy during this protocol. If the patient d oes not 
develop symptoms of ODS and responds to intravenous D5W therapy by [CONTACT_186613] 18 ([ADDRESS_220519] serum sodium), they will be eligible for the scheduled second study diuretic dose at 24 hours. 
Patients experiencing any neurologic symptoms or who do n ot respond to intravenous D5W 
Protocol Version #: 6 
Protocol Date: 10/27/2017  11 therapy by [CONTACT_186613] 1 8 ([ADDRESS_220520] serum sodium) will not be eligible for repeat study 
medication administration. All patients will be followed per the study protocol through Day 30.  
Hepatic toxicity  
Hepatotoxicity occurred in 3 patients in the TEMPO study, which evaluated the effects of 
Tolvaptan 60 -120mg daily in a polycystic kidney disease patient population. In all 3 patients, the 
hepatic toxicity occurred after 3 months of therapy and resolved wit h tolvaptan discontinuation. 
Our study protocol will exclude patients with advanced liver disease, consistent with the updated 
FDA package labeling recommendations, and will administer a lower dose for only 48 hours.  
 
 
Thiazides (Metolazone or Chlorothiaz ide) 
In accordance with previous trials evaluating combination thiazide and loop diuretics (DOSE, 
CARRESS -HF), the metabolic risks include gout, hypokalemia, and hyponatremia. The risks 
include: h yponatremia , hypokalemia , gout flare/attack, and c ardiac arrhythmias . In the 
CARRESS -HF study, ultrafiltration was compared to a step -wise diuretic protocol in 188 patients 
with hypervolemic, decompensated heart failure and worsening renal function. Of the 94 patients 
in the diuretic arm, 46% of participants receiv ed metolazone therapy. Only 3 (3%) patients 
experienced an electrolyte disorder, which included hypokalemia, hyponatremia, and 
hyperuricemia.  Arrhythmic events were not specifically reported. A retrospective comparison of 
intravenous and oral thiazide diu retics found the rate of hypokalemia, defined as a serum 
potassium < 4mEq/L, to be 71% in the oral thiazide group and 83% in the intravenous thiazide 
group.[ADDRESS_220521] of care 
practice.  
 
7.0 Reporting of Adverse Events or Unanticipated Problems involving Risk to Participants 
or Others  
 
A Serious Adverse Event (SAE)  is an adverse event that:  
â€¢ Results in death  
â€¢ Is life -threatening  
â€¢ Requires prolongation of hospi[INVESTIGATOR_186600]  
â€¢ Results in permanent impairment of a body function or permanent damage to a body 
structure  
â€¢ Requires medical or surgical intervention to preclude permanent impairment of a body 
function or permanent damage to a body structure  
Additionally, important medical events that may not result in death, be life -threatening,  
or prolong hospi[INVESTIGATOR_186601].  Example of 
such medical events include: allergic bronchospasm requiring intensive treatment in an  
emergency room or at home, blood dyscrasias or convulsions that do not result in prolonged 
hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. Medical and scientific 
judgment must be exercised when classifying events as serious.  
 
The det ermination of adverse event severity rests on medical judgment of a medically qualified 
investigator. The severity of SAEs will be graded using the following definitions:  
Protocol Version #: 6 
Protocol Date: 10/27/2017  12 â€¢ Mild : awareness of sign, symptom, or event, but easily tolerated;  
â€¢ Moderate : discomfor t enough to cause interference with usual activity and may warrant 
intervention;  
â€¢ Severe : incapacitating with inability to do usual activities or significantly affects clinical 
status, and warrants intervention.  
 
7.[ADDRESS_220522] assess the relationship of any SAE to the use of study 
drug, based on available information, using the following guidelines:  
Possibly Related  - There is a reasonable possibility that the adve rse event may have been caused 
by [CONTACT_5257]. The temporal relationship of the adverse event to study drug administration 
makes a causal relationship possible, and other drugs, therapeutic interventions or underlying 
conditions do not provide sufficien t explanation for the observed event.  
Not Possibly Related - It is unlikely that the event was caused by [CONTACT_5257]. The temporal 
relationship of the adverse event to the study drug administration makes causal relationship 
unlikely and other drugs, ther apeutic interventions or underlying conditions provide a more likely 
explanation for the event.  
Expectedness  - The expectedness of an adverse event or suspected adverse reaction shall be 
determined according to the package insert for U.S. marketed furosemi de and tolvaptan. Any AE 
that is not identified in nature, severity, or specificity in the current U.S. package insert is 
considered unexpected. Events described in the U.S. package insert as occurring with a class of 
drugs or as anticipated from the pharm acological properties of the drug, but not specifically 
mentioned as occurring with the particular drug under investigation are considered unexpected.  
 
7.2 Reporting of SAE  
All serious adverse events occurring from r andomization through the 30 day follow -up period 
will be collected. The Site Investigator is responsible for monitoring the  safety of patients 
enrolled into the study. The following adverse events  are anticipated, disease related -events in 
patients with decompensated heart failure however they s hould still be reported on the Serious 
Adverse Event form in the REDCAP Database (some  may require reporting as study endpoints):  
â€¢ New Atrial Arrhythmia : A â€œnewâ€ diagnosis of atrial arrhythmia (includes atrial 
fibrillation, atrial flutter, ectopic atrial ta chycardia) lasting > 30 seconds OR any atrial 
arrhythmia which causes hemodynamic instability (MAP < 60 and requiring intervention)  
â€¢ New Ventricular Arrhythmia : Ventricular tachycardia lasting longer than 30 seconds, or 
frequent non -sustained VT causing hemodynamic instability with MAP < 60 mmHg 
requiring intervention or > 1 intra -cardiac defibrillation or external cardiac defibrillation 
shock or ventricular fibrillation requiring defibrillation  
â€¢ Hypotension : SBP < [ADDRESS_220523] 
30 minutes or symptomatic hypotension necessitating clinical intervention (defined as 
vasopressor support, intravenous fluid boluses, or initiation of inotropes)  
â€¢ Myocardial infarction : a cardiac event including an elevat ion in troponin above baseline 
with our without ECG changes that is judged to be a myocardial infarction by [CONTACT_186614]  
â€¢ Cardiac arrest : any ventricular arrhythmic or pulseless electrical event that requires 
immediate life -sustaining  medical therapi[INVESTIGATOR_014]  
â€¢ Acute renal failure : A rise is serum creatinine of 1mg/dl or more from the baseline serum 
creatinine in the 48 hour treatment period  
â€¢ Acute renal failure  requiring dialysis : an acute renal failure event that began during the 
48 hour study  period and necessitates new hemodialysis during the hospi[INVESTIGATOR_186602] #: 6 
Protocol Date: 10/27/2017  13 â€¢ Worsening heart failure : the need for rescue therapy (additional open label loop diuretic,  
spi[INVESTIGATOR_186592] >75mg/day, eplerenone > 75mg/day, non -study thiazides (at a dose 
of metolaz one 2.5mg or greater equivalence) , systemic acetazolamide (for diuretic 
indication), tri amterene, amiloride, ultrafiltration, hemodialysis, or mechanical 
circulatory or respi[INVESTIGATOR_1413]) in the 48 hour treatment period  
â€¢ Death  
â€¢ Metabolic SAE (during 48 hour treatment period):  
o Severe Hypokalemia : Serum potassium value < 3.0mEq/L  
o Severe Hyponatremia : Serum sodium value < 130mEq/L and a decrease of 
5mEq/L or more from enrollment serum sodium  
o Overcorrection of serum sodium : increase in serum sodium from baseline by 
>12mEq/L in 24 hours, increase in >8mEq/L in 12 hours, or receipt of 
intravenous fluids because of symptoms of overcorrection of serum sodium 
regardless of the numerical rise  
o Hyperkalemia: serum potassium value >  5.5mEq/L  
o Gout:  acute gout attack requiring treatment with an anti -inflammatory agent  
 
All serious adverse events must be recorded in the Serious Adverse Event Record of the  
patientâ€™s REDCAP database . All serious adverse events should be monitored until s tabilization or  
resolution.  
 
Reporting to Local IRB . Investigators are also responsible for promptly reporting unexpected 
adverse  events (serious and non serious) to their reviewing IRB in accordance with local  
requirements.  The Vanderbilt investigational site will report DSM reports to the Vanderbilt IRB 
annually at the time of co ntinuing review at a minimum. If  [ADDRESS_220524] at the end of the study.  
 
7.3 Study Termination  
The study may be terminated based on review of serious  adverse events and unexpected events. If 
5 unexpected SAEs  occur this will trigger a temp orary halt to the study until  additional review of 
these events is conducted by [CONTACT_978] [INVESTIGATOR_32397] . 
 
8.0 Study Withdrawal/Discontinuation  
A patient may withdraw at the study at anytime. The patient will inform the site investigator of 
their desire to withdraw. All  study -based therapy will stop at this point, and the attending 
cardiologist will perform any further care. All study data collected to that time point will be 
included in the analysis. The withdrawal reason will be documented.  
The site investigator will withdraw patients requiring therapy for overcorrection of serum sodium 
who experience any neurologic symptoms or who do not respond to intravenous D5W therapy 
within 6 hours. All patients will be followed per the study protocol through Day 30.  
 
9.0 Statistical  Considerations  
9.1 Sample Size  
Protocol Version #: 6 
Protocol Date: 10/27/[ADDRESS_220525] statistical methods that allow our study to be realistic and achievable. Power 
calculations are difficult because of the lack of prospective trials comparing combination diuretic 
therapy and the numerous flaws in the methods of these previo us studies. We will utilize change 
in weight as the primary outcome because weight change has been utilized as a primary efficacy 
outcome in landmark heart failure diuretic trials (CARRESS -HF19) and has less standard 
deviation than net urine output. In pre vious studies standard deviation of weight loss changes 
between groups varied with an approximate value of 1.6kg.14, [ADDRESS_220526] 
the null hypot hesis that the population means of the experimental and control groups are equal 
with 82.3% power.   The Type I error probability associated with this test of this null hypothesis 
is 0.05.  
 
9.[ADDRESS_220527] which both 
chlorothiazide an d tolvaptan treatment arms will be individually compared. Parametric 
continuous variables will be presented as mean (standard deviation) and non -parametric 
continuous variables will be presented as median (interquartile range). Nominal data will be 
present ed as the number (percentage). We will employ a studentâ€™s t test for the independent 
continuous primary outcome variable  and other secondary outcomes  using metolazone as the 
comparison group for both intravenous chlorothiazide and oral tolvaptan. For secon dary 
outcomes, of which metolazone will again be the comparison group, fisherâ€™s exact test  will be 
used for secondary outcomes that are nominal data . A two tailed p -value of less than or equal to 
0.05 will be considered significant.  
 
10.0 Privacy/Confidentialit y Issues  
 
All study protocols and procedures will be submitted to the siteâ€™s Institutional Review Board for 
approval. All data collected will be stored in a secure REDCAP database, accessible only by [CONTACT_186615]. The following identifying informati on will be collected: age, medical record 
number, admission date, and discharge date. Patient -reported congestion score surveys will be de -
identified, using a study identification number. All patient -reported congestion score surveys and 
consent forms and will be stored in a locked cabinet in the site investigator's office. For statistical 
analyses, all identifying information will be removed. Candidates aged > [ADDRESS_220528] 12 months. All records will be stored in a secure REDCAP 
database.  
 
 
 
 
 
Protocol Version #: 6 
Protocol Date: 10/27/2017  15  
 
 
 
 
References  
1. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW. Temporal trends in 
clinical characteristics, treatments, and outcomes for heart failure hospi[INVESTIGATOR_602], 2002 
to 2004: findings from Acute Decompensated Heart Failure National Registry 
(ADHERE). Am Heart J 2007;153:1021 -8. 
2. AbrahamWT, Adams KF, Fonarow GC, Costanzo MR, Be rkowitz RL, LeJemtel TH, et 
al. In -hospi[INVESTIGATOR_186603]: an analysis from the Acute Decompensated Heart 
Failure National Registry (ADHERE). J Am Coll Cardiol 2005 ;46:57 -64. 
3.  Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et 
al. Effects of oral tolvaptan in patients hospi[INVESTIGATOR_85066]: the 
EVEREST Outcome Trial. JAMA 2007;297:1319 -31. 
4. CuffeMS, CaliffRM,AdamsKF, Benza R,Bour ge R,ColucciWS,et al. Short -term 
intravenous milrinone for acute exacerbation of chronic heart failure: a randomized 
controlled trial. JAMA 2002;287:1541 -7. 
5. Neuberg GW , Miller AB , O'Connor CM , Belkin RN , Carson PE , et al. Diuretic resistance 
predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:[ADDRESS_220529] of diuretic dosing on 
mortality in acute heart failure using a propensity -matched analysis. European Journal of 
Heart Failure (2011) 13, 1244 â€“1252.   
7. Testani JM 1, Cappola TP , Brensinger CM , Shannon RP , Kimmel SE . Interaction between 
loop diuretic -associated mortality and blood urea nitrogen concentration in chronic heart 
failure. JACC 2011;58:[ADDRESS_220530] Fail 2010;16:e1 -194. 
9. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, et al. 2013 
ACCF/AHA gu ideline for the management of heart failure: a report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. J Am Coll Cardiol 2013;62:1495 -539. 
10. Shah MR, Stevenson LW. Searching for evidence: Refracto ry questions in advanced 
heart failure. J Card Fail 2004;10:210 -8. 
11. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide -type 
diuretics in heart failure. J Am Coll Cardiol 2010;56:1527 -34. 
12. Metolazone [package insert]. Morgantown:  Mylan Pharmaceuticals; 2004.  
13. Michael Moranville, Suji Choi, Jennifer Hogg, Jonathan D. Rich Metolazone Versus 
Chlorothiazide as Add -On Therapy to Loop Diuretics in Patients with Acute 
Decompensated Heart Failure and Renal Insufficiency; [ADDRESS_220531] 2013.  
14. Kissling K, Pi[INVESTIGATOR_186604]. Comparison of the Effects of Combination Diuretic Therapy 
with Oral Hydrochlorothiazide or Intravenous Chlorothiazide in Patients Receiving 
Intravenous Furosemide Therapy f or the Treatment of Heart Failure. Pharmacotherapy. 
2014;34(8):882 â€“887. 
15. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J,Zampi[INVESTIGATOR_8614] M, et al. 
Vasopressin V2 -receptor blockade with tolvaptan in patients with chronic heart failure: 
results from a doub le-blind, randomized trial. Circulation 2003;107:2690 -6. 
16. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, Oâ€™Brien T, et al. A 
Protocol Version #: 6 
Protocol Date: 10/27/[ADDRESS_220532] Fail 2011;17:[ADDRESS_220533], in patients 
hospi[INVESTIGATOR_14850]: the EVEREST Clinical Status Trials. JAMA 
2007;297:1332 -43. 
18. Udelson JE, Bilsker M, Hauptman PJ, et al. A Multicenter, Randomized, Double -blind, 
Placebo -controlled Study of Tolvaptan Monotherapy Compared to Furosemide to the 
Combinations of Tolvaptan and Furosmide in Patients with Heart Failure and Systolic 
Dysfunction. J Cardiac Failure 2011; 17:973 -981.18  
19. Bart BA, Goldsmith SR, Lee KL, Redfield MM, Felker GM, O'Connor CM, e t al. 
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of 
CARRESS -HF, for the Heart Failure Clinical Research Network. J Card Fail. 
2012;18(3):176 -82. 
20. Sica DA. Metolazone and Its Role in Edema Management. CHF. 2003;9:100 -105. 
21. Goodman & Gillmanâ€™s The Pharmacological Basis of Therapeutics 12th edition.  
22. Borhani NO. Chlorothiazide and hydrochlorothiazide: a comparative study of their 
hypotensive, saluretic, and hyperuricemic action. Ann Intern Med 1960;53:342 â€“58. 
23. Channer KS, McLean KA, Lawson -Matthew P, Richardson M. Combination diuretic 
treatment in severe heart failure: a randomized controlled trial. Br Heart J. 1994;71:146 -
150. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Version #: 6 
Protocol Date: 10/27/2017  17  
 
 
 
 
Appendix A: Schedule of Study Assessments  
 Screen  Baseline  12 hrs  24hrs  36 hrs  48 hrs  Day 30  
(Phone 
Call)  
Informed Consent  x       
Inclusion/Exclusion 
Criteria  x       
Screening 
electrolytes, renal 
function, liver 
function , pregnancy 
status if applicable  x       
Vital Signs  x x x x x x  
Standing Weight   x  x  x  
Current 
Cardiovascular 
Medications   x  x  x  
Loop diuretic 
regimen evaluation  x x  x  x  
BMP  x x x x x x  
Biobank blood   x  x  x  
Biobank plasma   x  x  x  
Urine Collection  x x x x x x  
Congestion Score 
Assessment   x  x  x  
Adverse Event 
Assessment     x  x  
Outcomes 
Assessment       x x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Version #: 6 
Protocol Date: 10/27/2017  18  
 
 
 
 
Appendix B: Patient -Reported Congestion Score  
This score will be done at enrollment and repeated at 24 and 48 hours.  
 
 
 
 
 
 
 
 
 
 

Protocol Version #: 6 
Protocol Date: 10/27/2017  19  
 
 
 
Appendix C: 30 -Day Follow up Telephone Call Script  
The site investigator will perform this phone call at 30 Â± [ADDRESS_220534]. (name) from (Medical Center). I am calling to briefly follow up 
with you about the research study you participated in during your recent hospi[INVESTIGATOR_186605]. The study compared 3 different typ es of 
fluid removal medications in combination with furosemide (Lasix) and was called 
â€œComparison of oral thiazides v ersus intravenous thiazides versus  tolvaptan in 
combination with loop diuretics for diuretic resistant decompensated heart failure â€.  
 
Do y ou have time  now to complete the brief post -study survey that was mentioned to you 
at the start of the study ? It should take no more than [ADDRESS_220535] has deceased since discharge  
I am very sorry for  your loss. It is important that we ask 3 simple questions to understand 
this unfortunate event. Could you please tell me:  
â€¢ Date of death  
â€¢ Cause of death  
â€¢ Location of death  
o Out-of-hospi[INVESTIGATOR_307]  
o In-hospi[INVESTIGATOR_307]  
â–ª Initial reason for hospi[INVESTIGATOR_186606] (Medical Center) on (Discharge Date), have you experienced 
any of the following events?  
1. Admission to any hospi[INVESTIGATOR_307]?  
a. Admission reason:  
i. Heart failure  
ii. Heart rhythm issue  
iii. Low blood pressure  
iv. Heart attack  
v. Cardiac arrest  
vi. Kidney failure  
1. Was dialysis required?  
vii. Other (free text)  
 
2. Gone to any emergency room?  
a. Reason for emergency room visit:  
i. Heart failure  
ii. Heart rhythm issue  
Protocol Version #: 6 
Protocol Date: 10/27/[ADDRESS_220536]  
vi. Kidney failure  
vii. Other (free text)  
 
3. Any other serious health  event?  
a. Document event if so  
 
This ends your participation in this research study. Thank you very much for your 
participation in this research study and for your time today. Your participation is helpi[INVESTIGATOR_186607]. Do you have 
any other questions at this time?  
 
Goodbye.  
 
End of Script  
 
 
9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG
,QIRUPHG&RQVHQW'RFXPHQWIRU5HVHDUFK

3ULQFLSDO,QYHVWLJDWRU =DFKDU\/&R[3KDUP'  5HYLVLRQ'DWH 2FWREHU
6WXG\7LWOH &RPSDULVRQRIRUDOWKLD]LGHVYV LQWUDYHQRXVWKLD]LGHVYVWROYDS WDQLQFRPELQDWLRQZLWKORRSGLXU HWLFVIRUGLXUHWLFUHVLVWDQWG HFRPSHQVDWHG
KHDUWIDLOXUH
,QVWLWXWLRQ+RVSLWDO 9DQGHUELOW8QLYHUVLW\0HGLFDO&HQWHU 

RI7KLVLQIRUPHGFRQVHQWDSSOLHVWR DGXOWVDJHGRUJUHDWHUZL WKKHDUWIDLOXUH
1DPHRISDUWLFLSDQWBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBBBBBBBBBB$JHBBBBBBBBBBB

7KHIROORZLQJLVJLYHQWR\RX WRWHOO\RXDER XWWKLVUHVHDUFKV WXG\3OHDVHUHDGWKLVIRUPZLWKFDUHDQGDVNDQ\TXHVWLRQV\R X
PD\KDYHDERXWWKLVVWXG\<RXUTXHVWLRQVZLOOEHDQVZHUHG$ OVR\RXZLOOEHJLYHQDFR S\RIWKLVFRQVHQWIRUP

<RXGRQRWKDYHWREHLQWKLVUHVHDUFKVWXG\<RXPD\FKRRVHQR WWREHLQWKLVVWXG\DQGJHWRWKHUWUHDWPHQWVZLWKRXWFKDQJLQJ \RXU
KHDOWKFDUHVHUYLFHVRURWKHUULJKWV<RXFDQVWRSEHLQJLQWKL VVWXG\DWDQ\WLPH,IZHOHDUQVRPHWKLQJQHZWKDWPD\DIIHFW WKHULVNVRU
EHQHILWVRIWKLVVWXG\\RXZLOO EHWROGVRWKDW\RXFDQGHFLGH ZKHWKHURUQRW\RXVWLOOZDQWW REHLQWKLVVWXG\<RXUPHGL FDOUHFRUGZLOO
FRQWDLQDQRWHVD\LQJ\RXDUHLQDUHVHDUFKVWXG\$Q\RQH\RX DXWKRUL]HWRUHFHLYH\RXUPHGLFDOUHFRUGZLOODOVRJHWWKLVQRW H


 :KDWLVWKHSXUSRVHRIWKLVVWXG\"

<RXDUHEHLQJDVNHGWRWDNHSDUWLQWKLVUHVHDUFKVWXG\EHFDXVH \RXDUHDQDGXOWSDWLHQWZLWKWRRPXFKIOXLGIURP
KHDUWIDLOXUH+)ZKRUHTXLUHV GLXUHWLFWKHUDS\EH\RQGWKHXVH RIRUDORULQWUDYHQRXV,9ORRSGLXUHWLFWKHUDS\
/DVL[IXURVHPLGH%XPH[%XPHWDQLGH'HPDGH[WRUVHPLGHD ORQH7KHSXUSRVHRIWKLV VWXG\LVWRGHWHUPLQH
WKHQH[WRSWLRQIRUPH GLFDWLRQWRDGGWRWKHORRSGLXUHWLFVLQ RUGHUWRLQFUHDVHWKHDPRXQWRIXULQHRXWSXWDQGWR
LPSURYHV\PSWRPVRIDFXWHRUSURJUHVVLQJ+)6RPHSDWLHQWVZLWKH[WUDIOXLGI URP+)GHYHORSUHVLVWDQFHWROR RSGLXUHWLFWKHUDS\,QRUG HUWRRYHUFRPHWKLVLVVXH
WKHDGGLWLRQRIVHFRQGGLXUHWLFIURPDGLIIHUHQWFODVVLVRIWHQ XVHGLQFOXGLQJRUDOPHWROD]RQH,9FKORURWKLD]LGHRU
RUDOWROYDSWDQ'HVSLWHWKHFRPPR QSUDFWLFHRIXVLQJWKHVHGUXJ VWRJHWKHUZLWKORRSGLXUHWLFVZKHQUHVLVWDQFH
RFFXUVWKHEHVWZD\WRUHPRYHH[ FHVVIOXLGLQWKHVHVLWXDWLRQV LVXQNQRZQ 

 :KDWZLOOKDSSHQDQGKRZORQ JZLOO\RXEHLQWKHVWXG\"

3DWLHQWVZLWKH[WUDIOXLGIUR PKHDUWIDLOXUHZLOOEHVFUHHQHGI RUSRVVLEOHSDUWLFLSDWLRQLQWKLV VWXG\,I\RXDUHIRXQGWR
TXDOLI\IRUWKHVWXG\GXULQJVFUHH QLQJEDVHGRQLQFOXVLRQFKDU DFWHULVWLFVDQGDUHLQWHUH VWHGLQKHDULQJDERXWWKH
VWXG\ZHZLOOUHYLHZWKLVLQIRUPHGFRQVHQWZLWK\RX,I\RXGH FLGHWRWDNHSDUWZHZLOOKDY H\RXVLJQDQGGDWHWKLV
FRQVHQWIRUP
 ,I\RXDJUHHWRWKHVWXG\\RXZLOOEHWUHDWHGIRU\RXUKHDUW IDLOXUHVLPLODUWRQRUPDOFDUH<RXZLOOEHVWDUWHGRQD
OLWHUSHUGD\IOXLGDQGJUDPSHUGD\VRGLXPVDOWOLPLWDWLRQ $Q\VWDUWLQJVWRSSLQJ FOLQLFDOWHVWODEVGRVH
FKDQJHVPHGLFDWLRQFKDQJHV RURUGHUVRUSURFHGXUHVZLOOEHWK HGHFLVLRQRIWKHWUHDWLQJS K\VLFLDQV<RXZLOO
FRQWLQXHWRUHFHLYHDORRSGLXUHWLF+RZHYHUWRSUHYHQWGLIIHU HQFHLQGLXUHWLFWUHDWPHQW\RXU SK\VLFLDQVZLOOIROORZ
DVWDQGDUGL]HGDSSURDFKWRGRVLQJ\ RXUIXURVHPLGH/DVL[,QD GGLWLRQWRIXURVHPLGH/DVL[\RXZLOODOVREH
DVVLJQHGWRRQHRIWKUH HWUHDWPHQWJURXSV
LQWUDYHQRXV,9FKORURWKLD]LGHPJHYHU\KRXUVSOXVDQ RUDOSODFHERFDSVXOHHYHU\KRXUV
,9SODFHERLQIXVLRQHYHU\KRXUVSOXVDFDSVXOHFRQWDLQLQJ RUDOPHWROD]RQHPJHYHU\KRXUV
,9SODFHERLQIXVLRQHYHU\KRXUVSOXVDFDSVXOHFRQWDLQLQJ RUDOWROYDSWDQPJRQFHG DLO\LQWKHPRUQLQJDQG
SODFHERFDSVXOHLQWKHHYHQLQJ<RXDQG\RXUGRFWRUZLOOQRWNQRZZKLFKWUHDWPHQW\RXZLOOEHU HFHLYLQJ7KHXVHRIWKHSODFHERGUXJVLQWKLVWULDO
ZLOOEHXVHGWREOLQGWUHDWPHQWWRW KHSK\VLFLDQVDQGUHVHDUFKH UVKRZHYHU\RXZLOOEHUHF HLYLQJRQHRIWKHWKUHH
DFWLYHWUHDWPHQWVLQDGGLW LRQWRIXURVHPLGH/DVL[

 7KHGXUDWLRQRIWKHVWXG\ZLOOEH KRXUVIURPWKHILUVWGRVH RIVWXG\PHGLFDWLRQ'XULQJW KLVWLPH\RXUYLWDOVLJQV
VWDQGLQJZHLJKWDQGXULQHRXW SXWZLOOEHPRQLWRUHGDQG\RXZLO OEHIROORZHGFORVHO\$VQRWHGDOOSURFHGXUHV
PRQLWRULQJPHGLFDWLRQDQGWUHDWP HQWGHFLVLRQVH[FOXGLQJWKHG LXUHWLFVWKHUDS\ZLOO RFFXUDFFRUGLQJWRWKH
'DWHRI,5%$SSURYDO
I'DWHRI([SLUDWLRQRIRI
9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG
,QIRUPHG&RQVHQW'RFXPHQWIRU5HVHDUFK

3ULQFLSDO,QYHVWLJDWRU =DFKDU\/&R[3KDUP'  5HYLVLRQ'DWH 2FWREHU
6WXG\7LWOH &RPSDULVRQRIRUDOWKLD]LGHVYV LQWUDYHQRXVWKLD]LGHVYVWROYDS WDQLQFRPELQDWLRQZLWKORRSGLXU HWLFVIRUGLXUHWLFUHVLVWDQWG HFRPSHQVDWHG
KHDUWIDLOXUH
,QVWLWXWLRQ+RVSLWDO 9DQGHUELOW8QLYHUVLW\0HGLFDO&HQWHU 

RISK\VLFLDQGLVFUHWLRQDQGDFFRUGLQJWRVWDQGDUGRIFDUH<RXZLO OKDYHWKUHHH[WUDEORRGWHVWVIURPWKLVVWXG\7KHVH
ZLOORFFXUDWWKHVWDUWRIWKHVWXG \KRXUVODWHUDQGKR XUVODWHUDWWKHHQGRIWKHVWXG \(DFKRIWKHVHZLOOWDNH
PLOOLOLWHUVDERXWDQGDKDOIWDEOHVSRRQVRIEORRG:HZL OOFROOHFWVRPHRI\RXUXULQHWRVWXG\LQWKHODEHDFK
GD\2QHH[WUDTXHVWLRQ\RXZLOOKDYHHDFKGD\LVWRUDWH\RXU Â³VKRUWQHVVRIEUHDWKÂ´RQDVFDOH RIWRRQFHD
GD\7KLVZLOOWDNHOHVVWKDQ KDOIDPLQXWHWRFRPSOHWH


 &RVWVWR\RXLI\RXWDNHSDUWLQWKLVVWXG\

 ,I\RXDJUHHWRWDNHSDUWLQWKLVUHVHDUFKVWXG\\RXDQGRU\ RXULQVXUDQFHZLOOQRWKDYHWR SD\IRUWKHGLXUHWLF
WUHDWPHQWVDQGEORRGXULQHODEWHVWVXVHGIRUUHVHDUFK
+RZHYHU\RXDUHVWLOOUHVSRQVLEOHIRUSD\LQJIRUWKHXVXDOFDU H\RXZRXOGQRUPDOO\UHFHLYHIRUWKHWUHDWPHQWRI\RXU
LOOQHVV7KLVLQFOXGHVWUHDWPHQWVDQGWHVWV\RXZRXOGQHHGHYHQ LI\RXZHUHQRWLQWKLVV WXG\7KHVHFRVWVZLOOEH
ELOOHGWR\RXDQGRU\RXULQVXUDQFH
<RXKDYHWKHULJKWWRDVNZKDW LWPD\FRVW\RXWRWDNHSDUWLQ WKLVVWXG\ ,I\RXZRXOGOLNHDVVLVWDQFHILQDQFLDO
FRXQVHOLQJLVDYDLODEOHWKURXJ KWKH9DQGHUELOW )LQDQFLDO$VVLVW DQFH3URJUDP7KHVWXG\VWDIIFDQKHOS\RXFRQWDFW
WKLVSURJUDP<RXKDYHWKHULJKWWR FRQWDFW\RXULQVXUDQFHFRPS DQ\WRGLVFXVVWKHFRVWVRI \RXUURXWLQHFDUHQRQ
UHVHDUFKIXUWKHUEHIRUHFKRRVLQJWREHLQWKHVWXG\<RXPD\F KRRVHQRWWREHLQWKLVVWX G\LI\RXULQVXUDQFHGRHV
QRWSD\IRU\RXUURXWLQHFDUHQRQUHVHDUFKFRVWVDQG\RXUGRF WRUZLOOGLVFXVVRWKHUWUHD WPHQWSODQVZLWK\RX
 6LGHHIIHFWVDQGULVNVWKDW\RXFDQH[SHFWLI\RXWDNHSDUW LQWKLVVWXG\ 

7ROYDSWDQLVFRPPRQO\NQRZQWR FDXVHVRPHDOORUQRQHRIWKHV LGHHIIHFWVOLVWHGEHORZ
x 'U\PRXWKOLNHO\
x 7KLUVWOLNHO\
x 0DNLQJODUJHDPRXQWVRIXULQHDQGXULQDWLQJRIWHQOLNHO\
x &RQVWLSDWLRQLQIUHTXHQW
x :HDNQHVVLQIUHTXHQW
x )HYHULQIUHTXHQW
x ,QFUHDVHGEORRGVXJDU OHYHOVLQIUHTXHQW
x 'HSUHVVHGDSSHWLWHLQIUHTXHQW
x,QFUHDVHGVRGLXPLQWKHEORRGLQIUHTXHQW 
,IWKHVRGLXPFRQFHQWUDWLRQLVFRUUHFWHGWRRTXLFNO\WKHIROOR ZLQJVHULRXVVLGHHIIHF WVDUHUDUHEXWFRXOGKDSSHQ
x %UDLQLQMXU\UHVXOWLQJLQPRWRUVSHHFKGLVRUGHULQIUHTXHQW
x /RVVRIVSHHFKLQIUHTXHQW
x 'LIILFXOW\VZDOORZLQJLQIUHTXHQW
x ([WUHPHIDWLJXHLQIUHTXHQW
x ([WUHPHZHDNQHVVRI\RXUOH JVDQGDUPVLQIUHTXHQW
x 6HL]XUHVLQIUHTXHQW
x &RPDUDUH
x 'HDWKUDUH
:HZRXOGQRWDOORZ\RXWRSDUWLF LSDWHLQWKLVVWXG\LI\RXUVRG LXPZDVYHU\ORZ7RPLQLPL]H\RXUULVNRIVRGLXP
RYHUFRUUHFWLRQWKHVRGLXPFRQFHQWUDWLRQLQ\RXUEORRGZLOOEH PRQLWRUHGDQG\RXZLOOREVHUYHGIRUVLJQVRI
RYHUFRUUHFWLRQGXULQJWKHVWXG\6SHFLILFDOO\\RXUEORRGVRGL XPDPRXQWZLOOEHPHDVXUHGHYHU\KRXUV
'DWHRI,5%$SSURYDO
I'DWHRI([SLUDWLRQRIRI
9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG
,QIRUPHG&RQVHQW'RFXPHQWIRU5HVHDUFK

3ULQFLSDO,QYHVWLJDWRU =DFKDU\/&R[3KDUP'  5HYLVLRQ'DWH 2FWREHU
6WXG\7LWOH &RPSDULVRQRIRUDOWKLD]LGHVYV LQWUDYHQRXVWKLD]LGHVYVWROYDS WDQLQFRPELQDWLRQZLWKORRSGLXU HWLFVIRUGLXUHWLFUHVLVWDQWG HFRPSHQVDWHG
KHDUWIDLOXUH
,QVWLWXWLRQ+RVSLWDO 9DQGHUELOW8QLYHUVLW\0HGLFDO&HQWHU 

RI,I\RXUVHUXPVRGLXPLVIRXQGWREHWRRHOHYDWHGFRPSDUHGWRED VHOLQH\RXZLOOUHFHLYHVRPHDGGLWLRQDOVRGLXPODE
PRQLWRULQJDQG,9IOXLGVWRVORZ\ RXUVRGLXPFKDQJHV<RXZLOO EHREVHUYHGIRUVLJQVRIRYHUFRUUHFWLRQRIVRGLXP
:KHQ\RXUVHUXPVRGLXPLPSURYHVHQ RXJKWKHLQWUDYHQRXVIOXLGZ LOOEHVWRSSHG<RXZLOOKDYHDQRWKHUFKHFNRI\RXU
VHUXPVRGLXPDWKRXUVDQG\R XPD\UHFHLYHDGGLWLRQDOLQWUDYH QRXVIOXLGGHSHQGLQJXSRQWKHYDOXH
3DWLHQWVZKRGHYHORSRYHUFRUUHFWL RQRIWKHLUVHUXPVRGLXPZLOO EHHOLJLEOHWRFRQWLQXHL QWKHVWXG\LIWKH\KDYHQR
V\PSWRPVRIIDVWVRGLXPFKDQJHVDQGLIWKHLUVRGLXPUHVSRQGVWR WKHDGGLWLRQDO,9IOXLGLQKRXUV
%HLQJDSDUWRIWKLVVWXG\ZKLOHS UHJQDQWPD\H[SRVHWKHXQERUQ FKLOGWRXQQHFHVVDU\ ULVNV7KHUHIRUHSUHJQDQW
ZRPHQZLOOEHH[FOXGHGI URPWKHVWXG\,I\RXDUHDZRPDQRIFK LOGEHDULQJSRWHQWLDODSUHJQDQF\WHVWZLOOEHGRQHDQG
LWPXVWEHQHJDWLYHEHIRUH\ RXFDQHQWHUWKLVVWXG\
7KHIROORZLQJDUHFRPPRQVLGHHIIHFWVZLWKPHWROD]RQHDQGFKORU RWKLD]LGHDOWKRXJKWKHH[DFWOLNHOLKRRGIRUHDFKKDV
QRWEHHQGHILQHGKRZHYHUPRV WDUHQRWOLIHWKUHDWHQLQJRUVHY HUH
x /RZSRWDVVLXPOLNHO\
x /RZPDJQHVLXPOLNHO\
x +LJKXULFDFLGOLNHO\
x /RZFDOFLXPXQOLNHO\
x +LJKJOXFRVHXQOLNHO\
x &RQVWLSDWLRQXQOLNHO\
x 'LDU[LOCATION_006]HDXQOLNHO\
x 1DXVHDXQOLNHO\
x ,QFUHDVHLQVHUXPFUHDWLQLQHXQO LNHO\Â±DVLJQWKDWNLGQH\I XQFWLRQPD\EHDIIHFWHG
x $EQRUPDOKHDUW[LOCATION_006]\WKPXQOLNHO\EXWSRWHQWLDOO\VHULRXV
x /RZEORRGSUHVVXUHUDUH
x $OOHUJLFUHDFWLRQUDUH


3D\PHQWLQFDVH\RXDUHLQMXUHGEHFDXVHRIWKLVUHVHDUFKVW XG\

,ILWLVGHWHUPLQHGE\9DQGHUELOWDQGWKH,QYHVWLJDWRU>ZLWK6S RQVRULQSXW@WKDWDQLQMXU\RF FXUUHGDVDGLUHFWUHVXOWRIWKH
WHVWVRUWUHDWPHQWVWKDWDUHGRQHI RUUHVHDUFKWKHQ\RXDQGRU \RXULQVXUDQFHZLOOQRWKDYHWR SD\IRUWKHFRVWRILPPHGLDWH
PHGLFDOFDUHSURYLGHGDW9DQGHUELOWWRWUHDWWKHLQMXU\7KHUHDUHQRSODQVIRU9DQGHU ELOW>RUWKH6SRQVRU@WRSD\IRUD Q\LQMXU\FDXVHGE\WKHXVXDOFDUH\RXZRXOGQRUPDOO\
UHFHLYHIRUWUHDWLQJ\RXULOOQH VVRUWKHFRVWVRIDQ\DGGLWLRQD OFDUH7KHUHDUHQRSODQVIRU9DQGHUELOW>RUWKH6SRQVRU@WRJ LYH
\RXPRQH\IRUWKHLQMXU\

*RRGHIIHFWVWKDWPLJKWUH VXOWIURPWKLVVWXG\ 

D7KHEHQHILWVWRVFLHQFHDQGKXP DQNLQGWKDWPLJKWUHVXOWIURP WKLVVWXG\LQFOXGHDEHWW HUXQGHUVWDQGLQJRIGLXUHWLF
WUHDWPHQWLQGHFRPSHQVDWHGKHDUWIDLOXUHLQRUGHUWRRSWLPL]HF DUH
E7KHEHQHILWV\RXPLJKWJHWIURPEHLQJLQWKLVVWXG\PD\EHW KDWWKHV\PSWRPV\RXDUHH[SH ULHQFLQJIURPLQFUHDVHG
IOXLGVZLOOLPSURYH+RZHYHUWK HUHLVDFKDQFH\RXPD\QRWEHQ HILWSHUVRQDOO\IURPEHLQJ LQWKLVUHVHDUFKVWXG\

2WKHUWUHDWPHQWV\RX FRXOGJHWLI\RXGHFLGHQRWWREHLQW KLVVWXG\

,I\RXFKRRVHQRWWRWDNHSDUWLQWKLVVWXG\RWKHUFRPPRQO\SU HVFULEHGPHGLFLQHVDQGWUHDWP HQWVFRXOGEHXVHG<RXU
SK\VLFLDQVPD\XWLOL]HWKHVD PHWUHDWPHQWVDVXVHGLQWKLVWU LDOLI\RXHQGXSQRWEHLQJL QWKHVWXG\<RXGRQRWKDYHWRLQ 
WKLVVWXG\WRUHFHLYHWUHDWPHQWIRU\RXUFRQGLWLRQ
'DWHRI,5%$SSURYDO
I'DWHRI([SLUDWLRQRIRI
9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG
,QIRUPHG&RQVHQW'RFXPHQWIRU5HVHDUFK

3ULQFLSDO,QYHVWLJDWRU =DFKDU\/&R[3KDUP'  5HYLVLRQ'DWH 2FWREHU
6WXG\7LWOH &RPSDULVRQRIRUDOWKLD]LGHVYV LQWUDYHQRXVWKLD]LGHVYVWROYDS WDQLQFRPELQDWLRQZLWKORRSGLXU HWLFVIRUGLXUHWLFUHVLVWDQWG HFRPSHQVDWHG
KHDUWIDLOXUH
,QVWLWXWLRQ+RVSLWDO 9DQGHUELOW8QLYHUVLW\0HGLFDO&HQWHU 

RI
3D\PHQWVIRU\RXUWLPHVS HQWWDNLQJSDUWLQWKLVVWXG\RUH [SHQVHV

7KHUHZLOOEHQRWGLUHFWSD\PHQ WWR\RXIRUWDNLQJSDUWRIWKLV VWXG\<RXZLOOQRWJHWELOOHGRU\RXULQVXUDQFHFKDUJHGIRUD Q\
RIWKHVWXG\PHGLFDWLRQV

5HDVRQVZK\WKHVWXG\GRFWRUPD \WDNH\RXRXWRIWKLVVWXG\ 
7KHSK\VLFLDQVPD\WDNH\RXRXWRIWKHVWXG\DWWKHLUGLVFUHW LRQLIWKH\GHWHUPLQHDGLIIHUHQWW UHDWPHQWFRXUVHLQQHHGHG
VXFKDVXVHRIXOWUDILOWUDWLRQRULI\RXGHFLGHGWRQRWEHLQ WKHVWXG\DWDQ\SRLQW

:KDWZLOOKDSSHQLI\RXGHFLGHWR VWRSEHLQJLQWKLVVWXG\" 

,I\RXGHFLGHWRVWRSEHLQJSDUWRIWKHVWXG\\RXVKRXOGWHOO \RXUVWXG\GRFWRU'HFLGLQJWRQRWEHSDUWRIWKHVWXG\ZLOOQ RW
FKDQJH\RXUUHJXODUPHGLFDOFDUHLQDQ\ZD\

:KRWRFDOOIRUDQ\TXHVWLRQVRULQFDVH\RXDUHLQMXUHG

,I\RXVKRXOGKDYHDQ\TXHVWLRQVDERXWWKLVU HVHDUFKVWXG\RULI\RXIHHO\RXKDYHEHHQKXUWE\EHLQJDSDUWRIWKLV
VWXG\SOHDVHIHHOIUHHWRFRQWDFW'U=DFKDU\&R[DW ,I\RXFDQQRWUHDFKWKH UHVHDUFKVWDIISOHDVHSDJH
WKHVWXG\GRFWRU=DFKDU\ &R[DW 

)RUDGGLWLRQDOLQIRUPDWLRQDERXWJLYLQJFRQVHQWRU\RXUULJKWV DVDSHUVRQLQWKLVVWXG\ WRGLVFXVVSUREOHPVFRQFHUQV
DQGTXHVWLRQVRUWRRIIHULQSXW SOHDVHIHHOIUHHWRFDOOWKH 9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG2IILFHDW
RUWROOIUHH DW 

&OLQLFDO7ULDOV5HJLVWU\ 
$GHVFULSWLRQRIWKLVFOLQLF DOWULDOZLOOEHDYDLODEOHRQ ZZZFOLQLFDOWULDOVJRY DVUHTXLUHGE\86/DZ7KLV:HEVLWHZLOO
QRWLQFOXGHLQIRUPDWLRQWKDWFDQ LGHQWLI\\RX$WPRVWWKH:H EVLWHZLOOLQFOXGHDVX[COMPANY_003]U\RIWKHUHVXOWV<RXFDQ
VHDUFKWKLV:HEVLWHDWDQ\WLPH

&RQILGHQWLDOLW\ 

$OOGDWDFROOHFWHGZLOOEHVWRUHGZLWKRXWSHUVRQDOLGHQWLILFDWL RQLQDGDWDEDVHDFFHVVLEOHRQO\E\NH\VWXG\SHUVRQQHO
/LQNWRSDWLHQWLQIRUPDWLRQZLOOG RQHXVLQJDVWXG\LGHQWLILFDW LRQQXPEHU$OOSDWLHQWUHSRUWHGFRQJHVWLRQVFRUHVXUYH\V
DQGFRQVHQWIRUPVDQGZLOOEHVWRUHGLQDORFNHGFDELQHWLQWKHVLWHLQYHVWLJDWRUÂ¶VRIILFH

7KHLQYHVWLJDWRUVVSRQVRUVDQG9DQGHUELOWPD\VKDUH\RXULQIR UPDWLRQZLWKRXWLGHQWLILHUVWRRWKHUVRUXVHLWIRURWKHU
UHVHDUFKSURMHFWVQRWOLVWHGLQW KLVIRUP7KHVSRQVRUV9DQGHU ELOW'U&R[DQGKLVVWDIIZLOOFRPSO\ZLWKDQ\DQGDOO
ODZVUHJDUGLQJWKHSULYDF\RIVXFKLQIRUPDWLRQ7KHUHDUHQRS ODQVWRSD\\RXIRUWKHXVHRUWUDQVIHURIWKLVGH
LGHQWLILHGLQIRUPDWLRQ 


$XWKRUL]DWLRQWR8VH'LVFORVH 3URWHFWHG+HDOWK,QIRUPDWLRQ 
$OOHIIRUWVZLWKLQUHDVRQZLOOEHPDGHWRNHHS\RXUSURWHFWHGKHDOWKLQIRUPDWLRQ3+,SULYDWH3+, LV\RXUKHDOWK
LQIRUPDWLRQWKDWLVRUKDVEHHQJDWKHUHGRUNHSWE\9DQGHUELOW DVDUHVXOWRI\RXUKHDOWKF DUH7KLVLQFOXGHVGDWDJDWKHUHG
IRUUHVHDUFKVWXGLHVWKDWFDQE HWUDFHGEDFNWR\RX8VLQJRU VKDULQJÂ³GLVFORVXUHÂ´VXFKGDWDPXVWIROORZIHGHUDOSULYDF\
UXOHV%\VLJQLQJWKHFRQVHQWIRUWKLVVWXG\\RXDUHDJUHHLQJ Â³DXWKRUL]DWLRQÂ´WRWKHXVHVDQG OLNHO\VKDULQJRI\RXU3+, ,I
'DWHRI,5%$SSURYDO
I'DWHRI([SLUDWLRQRIRI

9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG
,QIRUPHG&RQVHQW'RFXPHQWIRU5HVHDUFK

3ULQFLSDO,QYHVWLJDWRU =DFKDU\/&R[3KDUP'  5HYLVLRQ'DWH 2FWREHU
6WXG\7LWOH &RPSDULVRQRIRUDOWKLD]LGHVYV LQWUDYHQRXVWKLD]LGHVYVWROYDS WDQLQFRPELQDWLRQZLWKORRSGLXU HWLFVIRUGLXUHWLFUHVLVWDQWG HFRPSHQVDWHG
KHDUWIDLOXUH
,QVWLWXWLRQ+RVSLWDO 9DQGHUELOW8QLYHUVLW\0HGLFDO&HQWHU 

RI\RXGHFLGHWREHLQWKLVUHVHDUFKVWXG\\RXDUHDOVRDJUHHLQJ WROHWWKHVWXG\WHDPXVHDQGV KDUH\RXU3+,DVGHVFULEHG
EHORZ

$VSDUWRIWKHVWXG\'U&R[DQGKLVVWXG\WHDPPD\VKDUHWKH UHVXOWVRI\RXUVWXG\DQGRUQRQVWXG\OLQNHGODEWHVW
FRQJHVWLRQVDVVHVVPH QWVFDUGLDFWHVWVDQG YLWDOVDVZHOODVS DUWVRI\RXUPHGLFDOUHFRUG WRWKHJURXSVQDPHGEHORZ
7KHVHJURXSVPD\LQFOXGHSHRS OHIURPWKH)HGHUDO*RYHUQPHQW2II LFHIRU+XPDQ5HVHDUFK3URWHFWLRQVDQGWKH
9DQGHUELOW8QLYHUVLW\,QVWLWXWLRQDO5HYLHZ%RDUG )HGHUDOSULYDF\UXOHVPD\QRWDSSO\WRWKHVHJURXSVWKH\KDY HWKHLURZQ
UXOHVDQGFRGHVWRDVVXUHWKD WDOOHIIRUWVZLWKLQUHDVRQZLOO EHPDGHWRNHHS\RXU3+,SULYDWH
7KHVWXG\UHVXOWVZLOOEHN HSWLQ\RXUUHVHDUFKUHFRUGIRUDWO HDVWVL[\HDUVDIWHUWKHVWXG\LV ILQLVKHG$WWKDWWLPHWKH
UHVHDUFKGDWDWKDWKDVQRWEH HQSXWLQ\RXUPHGLFDOUHFRUGZLOOEHNHSWIRUDQXQNQRZQOHQJWKRIWLPH $Q\UHVHDUFKGDWD
WKDWKDVEHHQSXWLQWR\RXUPH GLFDOUHFRUGZLOOEHNHSWIRUDQ XQNQRZQOHQJWKRIWLPH

8QOHVVWROGRWKHUZLVH\RXUFRQVHQWWRXVHRUVKDUH\RXU3+,GR HVQRWH[SLUH,I\RXFKDQJH\RXUPLQGZHDVNWKDW\RX
FRQWDFW'U=DFKDU\&R[3KDUP'L QZULWLQJDQGOHWKLPNQRZWKD W\RXZLWKGUDZ\RXUFRQVHQW+LVPDLOLQJDGGUHVVLV
$WWKDWWLPHZHZLOOVWR SJHWWLQJDQ\PRUHGDWDDERXW\RX%XWWKHKHDOWKGDWDZH
VWRUHGEHIRUH\RXZLWKGUHZ\RXUFRQ VHQWPD\VWLOOEHXVHGIRUU HSRUWLQJDQGUHVHDUFKTXDOLW\
,I\RXGHFLGHQRWWRWDNHSDUWLQWKLVUHVHDUFKVWXG\LWZLOO QRWDIIHFW\RXUWUHDWPHQWSD\PHQWRUHQUROOPHQWLQDQ\
KHDOWKSODQVRUDIIHFW\RXUDELOLW\WRJHWEHQHILWV<RXZLOOJHWDFRS\RIWKLVIRUPDIWHULWLVVLJQHG


67$7(0(17%<3(5621$*5((,1*72%(,17+,6678'<
 ,KDYHUHDGWKLVFRQVHQWIRUP DQGWKHUHVHDUFKVWXG\KDVEHHQ H[SODLQHGWRPHYHUEDOO\$OOP\TXHVWLRQV
KDYHEHHQDQVZHUHGDQG,IUHHO\DQGYROXQWDULO\FKRRVHWRWDNH SDUWLQWKLVVWXG\



'DWH    6LJQDWXUHRISDWLHQWYROXQWHHU    

&RQVHQWREWDLQHGE\ 
'DWH    6LJQDWXUH   

 BBBBBBBBBBBBBBB
    3ULQWHG1DPHDQG7LWOH      7LPH
'DWHRI,5%$SSURYDO
I'DWHRI([SLUDWLRQRIRI
